These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 8583370

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
    Crain SM, Shen KF.
    Brain Res; 1996 Nov 25; 741(1-2):275-83. PubMed ID: 9001733
    [Abstract] [Full Text] [Related]

  • 6. Dihydroetorphine: a potent analgesic: pharmacology, toxicology, pharmacokinetics, and clinical effects.
    Ohmori S, Morimoto Y.
    CNS Drug Rev; 2002 Nov 25; 8(4):391-404. PubMed ID: 12481194
    [Abstract] [Full Text] [Related]

  • 7. Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine.
    Niwa M, al-Essa LY, Ohta S, Kohno K, Nozaki M, Tsurumi K, Iwamura T, Kataoka T.
    Life Sci; 1995 Nov 25; 56(21):PL395-400. PubMed ID: 7739347
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Agonist and antagonist properties of dihydroetorphine for mu-opioid receptors in mice.
    Kamei J, Suzuki T, Nagase H.
    Neurosci Lett; 1996 Sep 06; 215(2):87-90. PubMed ID: 8888002
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R, Niizawa S, Koike K, Sagara T, Kanematsu K, Takayanagi I.
    Arch Int Pharmacodyn Ther; 1996 Sep 06; 331(2):136-52. PubMed ID: 8937625
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM.
    J Pharmacol Exp Ther; 2005 Nov 06; 315(2):821-7. PubMed ID: 16076937
    [Abstract] [Full Text] [Related]

  • 17. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
    Horan PJ, Wild KD, Kazmierski WM, Ferguson R, Hruby VJ, Weber SJ, Davis TP, Fang L, Knapp RJ, Yamamura HI.
    Eur J Pharmacol; 1993 Mar 16; 233(1):53-62. PubMed ID: 8386089
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Binding affinity to and dependence on some opioids in Sf9 insect cells expressing human mu-opioid receptor.
    Liu ZH, He Y, Jin WQ, Chen XJ, Zhang HP, Shen QX, Chi ZQ.
    Acta Pharmacol Sin; 2003 Sep 16; 24(9):859-63. PubMed ID: 12956932
    [Abstract] [Full Text] [Related]

  • 20. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
    Negri L, Improta G, Lattanzi R, Potenza RL, Luchetti F, Melchiorri P.
    Br J Pharmacol; 1995 Dec 16; 116(7):2931-8. PubMed ID: 8680727
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.